No abstract

No abstract

Key Points This trial evaluated frontline VR-CAP and R-CHOP therapy for patients with centrally confirmed non-GCB DLBCL. There was no significant improvement in response rates or long-term outcomes with VR-CAP vs R-CHOP in previously untreated non-GCB DLBCL.

Prostaglandin H (PGH) synthase (EC (6)(7)(8). However, earlier in vivo studies raised questions whether the pharmacologic activity of aspirin and other nonsteroidal antiinflammatory drugs is entirely mediated through this mechanism (1, 9). PGH synthase has been found to have a rapid turnover rate (half-life of 5-6 min) in the few tissues examined (10, 11). Cytokines and phorbol diesters are known to induce synthesis of the enzyme, thereby raising the level of PGH synthase protein severalfold over the basal levels (11)(12)(13)(14). In this communication, we report results of studies with cultured endothelial cells that indicate that aspirin and salicylate are able to inhibit the de novo synthesis of the enzyme by action at the level of gene expression.

Current treatment modalities can cure up to 70–80 % of patients with classical Hodgkin lymphoma. Approximately, 20–30 % of patients require further treatment options. Brentuximab vedotin has been approved for the treatment of relapsed and refractory Hodgkin lymphoma. In the present study, we report the experience with brentuximab vedotin as single agent in 58 patients with relapsed or refractory Hodgkin lymphoma. The objective response rate was 63.5 % with 13 complete responders (26.5 %) among 49 patients evaluated at the early phase of treatment (2–5 cycles). Upon treatment prolongation (≥6 cycles), 37 patients achieved a final objective response rate of 32.4 % with 21.6 % of complete and 10.8 % of partial response. Overall survival at 12 months was 70.6 %, and progression-free survival at 12 months was 32.8 %. Median overall survival could not be reached and median progression-free survival was 7 months. While the median duration of response was 9 months in the whole cohort, it was 11.5 months in the complete responders. Complete response rates in patients treated with >3 chemotherapy regimens before brentuximab vedotin were significantly lower (p = 0.016). Fourteen patients were subsequently transplanted. In conclusion, brentuximab vedotin provided a bridge to transplantation in approximately one quarter of the patients. The declining response rates during the course of treatment suggest that transplantation should be implemented early during brentuximab vedotin treatment.